Clinical data | |
---|---|
Other names | 5F-MDMB-2201; 5-Fluoro MDMB-PICA |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C21H29FN2O3 |
Molar mass | 376.472 g·mol−1 |
3D model (JSmol) | |
| |
|
5F-MDMB-PICA (MDMB-5F-PICA[2]) is a designer drug and synthetic cannabinoid.[3][4][5][6][7] In 2018, it was the fifth-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.[8]
5F-MDMB-PICA is a potent agonist of both the CB1 receptor and the CB2 receptor with EC50 values of 0.45 nM and 7.4 nM, respectively.[9]
In the United States, 5F-MDMB-PICA was temporarily emergency scheduled by the DEA in 2019.[10] In December 2019, the UNODC announced scheduling recommendations placing 5F-MDMB-PICA into Schedule II.[11] In the United States 5F-MDMB-PICA was made a permanent Schedule I Controlled Substance nationwide on April 7, 2022.[12]